Breast lumps classification: Difference between revisions
No edit summary |
|||
Line 14: | Line 14: | ||
'''Classification of [[breast lumps]] based on [[epithelial hyperplasia]]<ref name="pmid16034008">{{cite journal| author=Hartmann LC, Sellers TA, Frost MH, Lingle WL, Degnim AC, Ghosh K et al.| title=Benign breast disease and the risk of breast cancer. | journal=N Engl J Med | year= 2005 | volume= 353 | issue= 3 | pages= 229-37 | pmid=16034008 | doi=10.1056/NEJMoa044383 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16034008 }} </ref>'''<ref name="pmid1734106">{{cite journal| author=London SJ, Connolly JL, Schnitt SJ, Colditz GA| title=A prospective study of benign breast disease and the risk of breast cancer. | journal=JAMA | year= 1992 | volume= 267 | issue= 7 | pages= 941-4 | pmid=1734106 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=1734106 }}</ref> | '''Classification of [[breast lumps]] based on [[epithelial hyperplasia]]<ref name="pmid16034008">{{cite journal| author=Hartmann LC, Sellers TA, Frost MH, Lingle WL, Degnim AC, Ghosh K et al.| title=Benign breast disease and the risk of breast cancer. | journal=N Engl J Med | year= 2005 | volume= 353 | issue= 3 | pages= 229-37 | pmid=16034008 | doi=10.1056/NEJMoa044383 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16034008 }} </ref>'''<ref name="pmid1734106">{{cite journal| author=London SJ, Connolly JL, Schnitt SJ, Colditz GA| title=A prospective study of benign breast disease and the risk of breast cancer. | journal=JAMA | year= 1992 | volume= 267 | issue= 7 | pages= 941-4 | pmid=1734106 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=1734106 }}</ref> | ||
*Approximately 65% of all benign breast disease considered as [[nonproliferative|non-proliferative]] (NP) with relative cancer risk of 1.2, 1.4 times: | *Approximately 65% of all benign breast disease considered as [[nonproliferative|non-proliferative]] (NP) with relative cancer risk of 1.2, 1.4 times: | ||
**[[ | **[[Cyst]] | ||
***The most common | ***The most common type in non- proliferative category<ref name="pmid7110289">{{cite journal| author=Love SM, Gelman RS, Silen W| title=Sounding board. Fibrocystic "disease" of the breast--a nondisease? | journal=N Engl J Med | year= 1982 | volume= 307 | issue= 16 | pages= 1010-4 | pmid=7110289 | doi=10.1056/NEJM198210143071611 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=7110289 }} </ref> | ||
**[[Fibrosis]] | **[[Fibrosis]] | ||
** [[Fibroadenoma]] (simple) | ** [[Fibroadenoma]] (simple) | ||
Line 21: | Line 21: | ||
** [[Apocrine]] [[metaplasia]] (simple) | ** [[Apocrine]] [[metaplasia]] (simple) | ||
** Mild ductal [[hyperplasia]] | ** Mild ductal [[hyperplasia]] | ||
* Approximately 30% of total are classified as (PD) with relative cancer risk of 1.7, 2.1 times | * Approximately 30% of total are classified as (PD) with relative cancer risk of 1.7, 2.1 times<ref name="pmid3965932">{{cite journal| author=Dupont WD, Page DL| title=Risk factors for breast cancer in women with proliferative breast disease. | journal=N Engl J Med | year= 1985 | volume= 312 | issue= 3 | pages= 146-51 | pmid=3965932 | doi=10.1056/NEJM198501173120303 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=3965932 }}</ref> | ||
** Usual ductal [[hyperplasia]] | ** Usual ductal [[hyperplasia]] | ||
** Sclerosing adenosis | ** Sclerosing adenosis | ||
Line 27: | Line 27: | ||
** [[papilloma]] | ** [[papilloma]] | ||
** Radical scar | ** Radical scar | ||
* Approximately 5% to 8% of the rest regarded to PD with [[atypia]] and relative cancer risk more than 4 times | * Approximately 5% to 8% of the rest regarded to PD with [[atypia]] and relative cancer risk more than 4 times<ref name="pmid6275978">{{cite journal| author=Page DL, Dupont WD, Rogers LW, Landenberger M| title=Intraductal carcinoma of the breast: follow-up after biopsy only. | journal=Cancer | year= 1982 | volume= 49 | issue= 4 | pages= 751-8 | pmid=6275978 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=6275978 }}</ref> | ||
** Atypical lobar [[hyperplasia]] | ** Atypical lobar [[hyperplasia]] | ||
** [[Lobular]] [[carcinoma]] [[in situ]] | ** [[Lobular]] [[carcinoma]] [[in situ]] |
Revision as of 19:51, 21 December 2018
Breast lumps Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Breast lumps classification On the Web |
American Roentgen Ray Society Images of Breast lumps classification |
Risk calculators and risk factors for Breast lumps classification |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Shadan Mehraban, M.D.[2]
Overview
Breast lumps may be classified according to epithelial hyperplasia into 3 subtypes: non-proliferative, proliferative disease and proliferative disease without atypia.
Breast lumps may be classified into 3 subtypes based on histological regions: lobular region, ductal region, different origins.
Classification
Classification of breast lumps based on epithelial hyperplasia[1][2]
- Approximately 65% of all benign breast disease considered as non-proliferative (NP) with relative cancer risk of 1.2, 1.4 times:
- Cyst
- The most common type in non- proliferative category[3]
- Fibrosis
- Fibroadenoma (simple)
- Columnar alteration (Simple)
- Apocrine metaplasia (simple)
- Mild ductal hyperplasia
- Cyst
- Approximately 30% of total are classified as (PD) with relative cancer risk of 1.7, 2.1 times[4]
- Usual ductal hyperplasia
- Sclerosing adenosis
- Columnar hyperplasia
- papilloma
- Radical scar
- Approximately 5% to 8% of the rest regarded to PD with atypia and relative cancer risk more than 4 times[5]
- Atypical lobar hyperplasia
- Lobular carcinoma in situ
- Atypical ductal hyperplasia
- Unclear risk
Classification of benign breast lesion regarding to histologist region:[6]
- Terminal and lobular ducts
- Acinar distention
- Intralobular connective tissue proliferation
- Sclerosing adenosis
- Fibroadenoma
- Phyllodes tumor
- Hamartoma
- Epithelial changes in terminal duct lobular units (TDLU)
- Apocrine metaplasia
- Ductal and lobular hyperplasia, usual and typical
- Papillomatosis
- Intracystic papilloma
- Ductal system
- Lesion of different origin
- Fatty tissue lesion
- Lipoma
- Liponecrosis
- Fibrous tissue lesions
- Focal fibrosis
- Diabetic mastopathy
- Pseudoangiomatous stromal hyperplasia (PASH)
- Myofibroblastoma
- Vascular origin
- Inflammatory origin
- Mastitis/abscess
- Tuberculosis and sarcoidosis
- Foreign body granuloma and siliconoma
- Lymph node origin
- Fatty tissue lesion
References
- ↑ Hartmann LC, Sellers TA, Frost MH, Lingle WL, Degnim AC, Ghosh K; et al. (2005). "Benign breast disease and the risk of breast cancer". N Engl J Med. 353 (3): 229–37. doi:10.1056/NEJMoa044383. PMID 16034008.
- ↑ London SJ, Connolly JL, Schnitt SJ, Colditz GA (1992). "A prospective study of benign breast disease and the risk of breast cancer". JAMA. 267 (7): 941–4. PMID 1734106.
- ↑ Love SM, Gelman RS, Silen W (1982). "Sounding board. Fibrocystic "disease" of the breast--a nondisease?". N Engl J Med. 307 (16): 1010–4. doi:10.1056/NEJM198210143071611. PMID 7110289.
- ↑ Dupont WD, Page DL (1985). "Risk factors for breast cancer in women with proliferative breast disease". N Engl J Med. 312 (3): 146–51. doi:10.1056/NEJM198501173120303. PMID 3965932.
- ↑ Page DL, Dupont WD, Rogers LW, Landenberger M (1982). "Intraductal carcinoma of the breast: follow-up after biopsy only". Cancer. 49 (4): 751–8. PMID 6275978.
- ↑ Lanyi, M (2003). Mammography : diagnosis and pathological analysis. Berlin New York: Springer-Verlag. ISBN 9783540441137.